EPS Creative Health Technology Group Limited's (HKG:3860) Shares Climb 65% But Its Business Is Yet to Catch Up
EPS Creative Health Technology Group Limited's (HKG:3860) Shares Climb 65% But Its Business Is Yet to Catch Up
EPS Creative Health Technology Group Limited (HKG:3860) shareholders would be excited to see that the share price has had a great month, posting a 65% gain and recovering from prior weakness. The last 30 days bring the annual gain to a very sharp 53%.
易普生创意健康科技集团有限公司(HKG：3860)股东将兴奋地看到，股价在一个月内表现出色，上涨了65%，并从之前的疲软中恢复过来。在过去的30天里，年度涨幅达到了非常大的53%。
Since its price has surged higher, given close to half the companies operating in Hong Kong's Luxury industry have price-to-sales ratios (or "P/S") below 0.6x, you may consider EPS Creative Health Technology Group as a stock to potentially avoid with its 1.5x P/S ratio. However, the P/S might be high for a reason and it requires further investigation to determine if it's justified.
由于其价格飙升，鉴于近一半在香港奢侈品行业运营的公司的市销率(P/S)低于0.6倍，你可以考虑将每股收益创意健康科技集团作为一只股票，其市盈率/S比率为1.5倍，可能会被规避。然而，P/S可能是有原因的，需要进一步调查才能确定是否合理。
See our latest analysis for EPS Creative Health Technology Group
查看我们对EPS创意健康科技集团的最新分析
What Does EPS Creative Health Technology Group's Recent Performance Look Like?
EPS创意健康科技集团近期的表现如何？
For instance, EPS Creative Health Technology Group's receding revenue in recent times would have to be some food for thought. Perhaps the market believes the company can do enough to outperform the rest of the industry in the near future, which is keeping the P/S ratio high. If not, then existing shareholders may be quite nervous about the viability of the share price.
例如，EPS创意健康科技集团(EPS Creative Health Technology Group)最近不断下滑的收入将不得不引起一些思考。或许，市场认为该公司在不久的将来可以做得足够好，跑赢业内其他公司，这使得市盈率和S的市盈率保持在较高水平。如果不是，那么现有股东可能会对股价的生存能力感到相当紧张。
Do Revenue Forecasts Match The High P/S Ratio?
收入预测是否与高市盈率相匹配？
The only time you'd be truly comfortable seeing a P/S as high as EPS Creative Health Technology Group's is when the company's growth is on track to outshine the industry.
只有当公司的增长有望超越行业时，你才会真正放心地看到每股收益创意健康科技集团这样高的市盈率/S。
In reviewing the last year of financials, we were disheartened to see the company's revenues fell to the tune of 13%. This means it has also seen a slide in revenue over the longer-term as revenue is down 16% in total over the last three years. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.
回顾过去一年的财务状况，我们沮丧地看到该公司的收入下降到了13%。这意味着它的长期营收也出现了下滑，因为过去三年的总营收下降了16%。因此，公平地说，最近的收入增长对公司来说是不可取的。
Weighing that medium-term revenue trajectory against the broader industry's one-year forecast for expansion of 13% shows it's an unpleasant look.
将这一中期收入轨迹与整个行业一年内增长13%的预测进行比较，可以看出这是一个令人不快的前景。
In light of this, it's alarming that EPS Creative Health Technology Group's P/S sits above the majority of other companies. It seems most investors are ignoring the recent poor growth rate and are hoping for a turnaround in the company's business prospects. Only the boldest would assume these prices are sustainable as a continuation of recent revenue trends is likely to weigh heavily on the share price eventually.
有鉴于此，EPS创意健康科技集团的P/S坐在其他大多数公司的前面，这是令人震惊的。似乎大多数投资者都忽视了最近糟糕的增长率，并希望该公司的业务前景有所好转。只有最大胆的人才会认为这些价格是可持续的，因为最近收入趋势的延续最终可能会对股价造成沉重压力。
The Key Takeaway
关键的外卖
The large bounce in EPS Creative Health Technology Group's shares has lifted the company's P/S handsomely. It's argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.
EPS创意健康科技集团股价的大幅反弹大幅提振了该公司的市盈率/S。有人认为，在某些行业中，市销率是衡量价值的次要指标，但它可能是一个强大的商业信心指标。
We've established that EPS Creative Health Technology Group currently trades on a much higher than expected P/S since its recent revenues have been in decline over the medium-term. When we see revenue heading backwards and underperforming the industry forecasts, we feel the possibility of the share price declining is very real, bringing the P/S back into the realm of reasonability. If recent medium-term revenue trends continue, it will place shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.
我们已经确定，EPS创意健康科技集团目前的市盈率(P/S)远高于预期，因为其最近的收入在中期内一直在下降。当我们看到营收回落，表现逊于行业预期时，我们觉得股价下跌的可能性非常真实，使市盈率/S重新回到合理的境界。如果近期的中期营收趋势持续下去，将使股东的投资面临重大风险，潜在投资者面临支付过高溢价的危险。
Don't forget that there may be other risks. For instance, we've identified 3 warning signs for EPS Creative Health Technology Group (2 don't sit too well with us) you should be aware of.
别忘了，可能还有其他风险。例如，我们已经确定EPS创意健康科技集团的3个警示标志(2)不要和我们坐得太好)你应该知道。
If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.
如果过去收益增长稳健的公司符合你的胃口，你可能想看看这个免费其他盈利增长强劲、市盈率较低的公司的集合。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗？担心内容吗？ 保持联系直接与我们联系。或者，也可以给编辑组发电子邮件，地址是implywallst.com。
本文由Simply Wall St.撰写，具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论，我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议，也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意，我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。